Menu
Back to Journals » OncoTargets and Therapy » Volume 3
The bevacizumab experience in advanced renal cell carcinoma
Authors Harshman L, Srinivas S
Published 15 September 2010 Volume 2010:3 Pages 179—189
DOI https://doi.org/10.2147/OTT.S8157
Review by Single anonymous peer review
Peer reviewer comments 3
Lauren C Harshman, Sandy Srinivas
Division of Oncology, Stanford University School of Medicine, Stanford, California, USA
Abstract: Bevacizumab in combination with interferon alfa is now approved for treatment-naïve advanced renal cell carcinoma (RCC) in both the US and Europe. Its objective response rates of 30% and progression-free survival rates of 9–10 months are comparable to the other approved first-line multityrosine kinase inhibitors, sunitinib and pazopanib. Its advantages include a different toxicity profile and assurance of administration compliance given its intravenous formulation. Enthusiasm for its use is blunted by the increased costs, the potential infusion-related reactions, the associated interferon-related toxicities, and the inconvenience of its nonoral formulation. Further study is warranted to assess its efficacy both as a single agent and in combination with the targeted agents and other immunotherapies. With multiple agents now available for the treatment of advanced RCC, identification of patient and tumor-specific biomarkers to inform our choice of first-line therapy and the proper sequence of subsequent therapies is imperative.
Keywords: bevacizumab, renal cell carcinoma, interferon alfa
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.